Skip to content

Strain Echo in Acute Heart Failure

The Utility of Strain Echocardiography in the Management of Acute Heart Failure

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02371642
Acronym
Strain Echo
Enrollment
120
Registered
2015-02-25
Start date
2015-01-31
Completion date
Unknown
Last updated
2016-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Echocardiography

Brief summary

The purpose of this project is to evaluate the utility of left ventricular strain as part of the assessment of patients in the emergency department with acute heart failure (HF). The central hypothesis of the investigation is that left ventricular strain will prove to be a treatment response variable in patients with acute HF. Patients who are being treated for acute HF with intravenous (IV) vasoactive medications (diuretics, vasodilators, inotropes) will be eligible for enrollment. Patients who give written consent will receive a focused bedside echocardiogram within 30 minutes of the initiation of therapy for acute HF. Images that are captured during this echocardiogram will be interpreted by a blinded cardiologist offline. 23 hours after this initial focused echocardiogram a member of the study team will perform a follow-up focused echocardiogram, capturing the same images that will then be interpreted by a blinded cardiologist offline. Offline analysis will be performed using a proprietary software package from General Electric called Automated Function Imaging (AFI). The AFI software will be used to calculate longitudinal strain of the left ventricle (LV). Regional and global strain values will be calculated for each focused echocardiogram for each subject. It is our hypothesis that LV strain will demonstrate improvements from the initial echocardiogram to the follow-up echocardiogram, unlike other echocardiographic indices in HF such as LV ejection fraction.

Interventions

None listed

Sponsors

Wayne State University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years of age or greater * Ability for the patient to provide written informed consent * Planned treatment with intravenous (IV) medications (diuretics, vasodilators, inotropes) for acute HF

Exclusion criteria

* Need for emergent, resuscitative intervention (e.g., cardiopulmonary resuscitation, endotracheal intubation) * Rapid atrial fibrillation or other arrhythmia that requires IV rate or rhythm control * Plans for emergent percutaneous coronary intervention (PCI) from the ED * Pregnancy * Incarceration * history of cardiac transplant * planned transfer to another institution

Design outcomes

Primary

MeasureTime frame
change in global longitudinal strain (GLS)23 hours

Secondary

MeasureTime frameDescription
Readmission rate30 daysReadmission for heart failure or other cardiovascular-related events

Countries

United States

Contacts

Primary ContactMark J Favot, M.D.
mfavot@med.wayne.edu313-966-1020
Backup ContactLaura Gowland, RDCS
lgowland@med.wayne.edu313-966-1020

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026